In focus · trending topic

menin-MLL inhibitor

61 stories · following the connections

Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer

By Nasdaq OMXFeb 15, 2018, 4:00 PM UTC

Kura Oncology to Present at the Leerink Partners 7th Annual Global Healthcare Conference

By Nasdaq OMXFeb 8, 2018, 12:31 PM UTC

Kura Oncology Added to Nasdaq Biotechnology Index

By Nasdaq OMXDec 18, 2017, 12:30 PM UTC

Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers

By Nasdaq OMXDec 11, 2017, 3:00 PM UTC

Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia

By Nasdaq OMXDec 10, 2017, 2:00 PM UTC

Kura Oncology to Host Investor Day on November 16, 2017

By Nasdaq OMXNov 9, 2017, 9:05 PM UTC

Kura Oncology Reports Third Quarter 2017 Financial Results and Provides Corporate Update

By Nasdaq OMXNov 7, 2017, 9:06 PM UTC

Kura Oncology Announces Upcoming Presentations at American Society of Hematology Annual Meeting

By Nasdaq OMXNov 1, 2017, 8:06 PM UTC